A 28-year-old woman from Mumbai with known seropositive myasthenia gravis (anti-AChR antibodies positive) presents with progressive generalized weakness, ptosis, and bulbar symptoms over 2 weeks despite being on pyridostigmine 60 mg QID. She has no fever, normal chest X-ray, and recent blood cultures are negative. Her thyroid function tests are normal. On examination, she has severe bilateral ptosis, ophthalmoplegia, and weak voice. Vital capacity is 1.8 L (predicted 3.2 L). What is the most appropriate next step in management?

Explanation

## Diagnosis: Myasthenic Crisis Requiring Acute Immunotherapy **Key Point:** This patient has myasthenic crisis — acute, life-threatening worsening of MG with respiratory compromise (vital capacity <2.5 L). She requires immediate plasma exchange or IVIg plus corticosteroids, NOT further anticholinesterase escalation. ### Recognition of Myasthenic Crisis | Criterion | Finding in This Case | |-----------|----------------------| | **Vital capacity** | 1.8 L (critical; <2.5 L = respiratory risk) | | **Bulbar weakness** | Present (weak voice, dysphagia risk) | | **Ophthalmoplegia** | Bilateral, severe | | **Progression despite treatment** | Yes, on maximum anticholinesterase | | **Fever/infection** | No (rules out cholinergic crisis trigger) | **High-Yield:** Vital capacity <2.5 L is a **red flag for impending respiratory failure** in MG. Intubation may be needed within hours. ### Why Increasing Pyridostigmine Is Wrong **Clinical Pearl:** In myasthenic crisis, anticholinesterase drugs reach a plateau of efficacy and may worsen symptoms if pushed further. The crisis requires **immunomodulation**, not more acetylcholinesterase inhibition. The underlying problem is insufficient acetylcholine receptors, not insufficient acetylcholine. ### Acute Management Algorithm for Myasthenic Crisis ```mermaid flowchart TD A[Myasthenic Crisis:<br/>VC < 2.5 L, bulbar weakness]:::urgent --> B[Admit ICU<br/>Continuous monitoring]:::action B --> C{Respiratory support needed?}:::decision C -->|Yes| D[Intubation + mechanical ventilation]:::action C -->|No| E[High-flow O₂, prepare for intubation]:::action A --> F[Acute Immunotherapy]:::action F --> G{Choose ONE:}:::decision G -->|First-line| H[Plasma Exchange<br/>5 exchanges over 7-10 days]:::action G -->|Alternative| I[IVIg 2 g/kg over 3-5 days]:::action F --> J[Add IV Methylprednisolone<br/>1 g daily × 3-5 days]:::action J --> K[Transition to oral prednisolone<br/>1 mg/kg/day, taper over weeks]:::action H --> L[Response expected in 3-7 days]:::outcome I --> L ``` ### First-Line Acute Therapies | Modality | Mechanism | Onset | Duration | Advantages | Disadvantages | |----------|-----------|-------|----------|------------|---------------| | **Plasma Exchange** | Removes pathogenic AChR antibodies | 24–48 hrs | 2–4 weeks | Rapid, effective | Vascular access, infection risk | | **IVIg** | Blocks Fc receptors, reduces antibody-mediated complement activation | 3–5 days | 3–4 weeks | Easier access, safer | More expensive, slower onset | | **IV Methylprednisolone** | Suppresses T-cell activation, reduces antibody production | 3–7 days | Weeks to months | Synergizes with PE/IVIg | Hyperglycemia, infection risk | **Mnemonic: PICE for acute MG crisis:** - **P**lasma exchange OR IVIg - **I**nfection control (monitor for aspiration) - **C**orticosteroids (IV methylprednisolone) - **E**ndotracheal intubation if VC <2.5 L or declining ### Why Each Distractor Is Suboptimal **Option A (Increase pyridostigmine):** - Anticholinesterase drugs have a ceiling effect in crisis - Further increases risk cholinergic toxicity without benefit - Does not address the immune-mediated destruction of AChR **Option C (CT chest + azathioprine monotherapy):** - Azathioprine is a **maintenance** immunosuppressant (onset 3–6 months), not acute therapy - CT chest is appropriate for staging but should not delay acute treatment - Thymoma is present in ~10–15% of anti-AChR+ MG; imaging is part of workup but not urgent in crisis **Option D (Mechanical ventilation without immunotherapy):** - Supportive care alone does not resolve the underlying immune pathology - Ventilation buys time but must be paired with plasma exchange or IVIg - Mortality without immunotherapy is high ### Long-Term Management After Crisis 1. **Thymectomy:** Indicated in anti-AChR+ MG; improves remission rates 2. **Maintenance immunosuppression:** Prednisolone + azathioprine or mycophenolate mofetil 3. **Anticholinesterase:** Continue at lowest effective dose [cite:Harrison 21e Ch 382]